The global next generation antibody therapeutics market is projected to grow from USD 5.45 billion to USD 5.76 billion by 2035, with a modest 1% CAGR. Growth is driven by advances in biotechnology, targeted treatments, and expanding clinical pipelines for cancer, rare diseases, and cardiovascular conditions. Immunocytokines and combination therapies are expected to demonstrate the strongest growth potential, while North America is projected to maintain approximately 64% market share.

Telix Pharmaceuticals has announced a strategic merger agreement to acquire ITM Isotope Technologies Munich for $1.65 billion upfront, with up to $700 million in contingent consideration. The merger combines Telix's therapeutic pipeline with ITM's world-leading radioisotope production capabilities and ITM-11 (177Lu-edotreotide), a Phase 3-completed candidate for neuroendocrine tumors. The combined entity is expected to generate over $1.3 billion in pro forma 2026 revenue and achieve positive EBITDA by 2027.

Telix Pharmaceuticals announced that David Gill has been appointed as Chair of the Board, effective immediately. Gill, who joined as a Non-Executive Director in May 2026, brings over 35 years of life sciences executive experience, including expertise in radiopharmaceuticals, capital markets, and corporate strategy. He succeeds Dr. Mark Nelson, who served as interim Chair and will remain as a Non-Executive Director.

Telix Pharmaceuticals announced it will release its half-year financial results for June 30, 2026 on August 20, 2026, with an accompanying investor webcast and conference call. The company reported Q2 2026 revenue of US$247M with strong commercial momentum and pipeline progress across its radiopharmaceutical portfolio.

Telix Pharmaceuticals announced publication of ProstACT SELECT Phase 1 study results in peer-reviewed journal Cancers, demonstrating that 68Ga-PSMA-PET imaging can reliably identify patients suitable for TLX591-Tx therapy. The study showed TLX591-Tx achieved a median radiographic progression-free survival of 8.8 months with a manageable safety profile in advanced metastatic prostate cancer patients, supporting the ongoing Phase 3 ProstACT Global trial.

Telix Pharmaceuticals reported Q2 2026 group revenue of US$247 million (up 7% QoQ, 21% YoY) with Precision Medicine revenue reaching US$202 million (up 30% YoY). The company achieved key regulatory milestones including FDA alignment on TLX591-Tx Phase 3 trial progression and near-completion of BiPASS patient enrollment. FY 2026 revenue guidance remains on track to exceed US$1 billion. Telix also entered a strategic collaboration with Regeneron and completed a convertible bond refinancing.

Telix Pharmaceuticals announced successful alignment with the FDA on the Part 2 protocol design of its ProstACT Global Phase 3 trial for TLX591-Tx in metastatic castration resistant prostate cancer. The FDA confirmed that Part 1 safety data is sufficient to progress Part 2 into the U.S., where the therapeutic candidate will be tested in combination with three standard-of-care therapies. The company plans to submit an IND amendment to initiate Part 2 enrollment in the U.S.

Telix Pharmaceuticals announced an educational webinar scheduled for June 29-30, 2026, featuring clinical updates on neuro-oncology and theranostics approaches to address unmet needs in glioma and glioblastoma treatment. The webinar will include presentations from Telix's Chief Medical Officer and fireside chats with leading nuclear medicine and neuro-oncology physicians from European institutions.

Over 200 companies are advancing 220+ pipeline glioblastoma drugs across various clinical development stages. The pipeline is shifting from conventional chemotherapy toward targeted therapy, immunotherapy, and epigenetic approaches. Key candidates include Kazia Therapeutics' Paxalisib (Phase III), BPG Bio's BPM31510, and immunotherapy programs from Inovio Pharmaceuticals. Recent developments include Telix's first radiopharmaceutical therapy entering Phase III trials and multiple clinical collaborations announced in early 2026.

The metastatic prostate cancer market is projected to experience robust growth through 2036, valued at USD 11.5 billion in 2025 across seven major markets. The market is transitioning from conventional androgen deprivation therapy toward combination-based, biomarker-driven approaches, with novel therapies such as PSMA-targeted radioligand therapies and PARP inhibitors reshaping the treatment paradigm. Key emerging drugs include 225Ac-PSMA-617, 177Lu-DOTA-rosopatamab, and cabozantinib, with multiple pharmaceutical companies advancing innovative treatments in clinical trials.

Telix Pharmaceuticals announced positive Phase 3 Part 1 data for TLX591-Tx, a lutetium radio antibody-drug conjugate for metastatic castration-resistant prostate cancer. The study of 36 patients showed acceptable safety and tolerability when combined with standard-of-care therapies, with no new safety signals. Radiation exposure remained below established safety limits, and the company has initiated Part 2 randomized expansion in multiple jurisdictions.

Telix Pharmaceuticals announced completion of patient enrolment in the IPAX-2 Phase 1 study of TLX101-Tx (¹³¹I-iodofalan) for newly diagnosed glioblastoma. The study reached its maximum dose of 10GBq with no dose-limiting toxicities observed. The company is also advancing the pivotal IPAX BrIGHT Phase 3 trial for recurrent glioblastoma, marking the first radiopharmaceutical therapy to enter Phase 3 development for this indication.